The present review describes the biology of human leukocyte antigen (HLA) haplotype mismatched ("haploidentical") transplantation, its translation to clinical practice to cure leukemia and the results of current transplantation protocols. The 1990s saw what had been major drawbacks of haploidentical transplantation, i.e., very strong host-versusgraft and graft-versus-host alloresponses which led respectively to rejection and graftversus-host disease (GVHD), being overcome through transplantation of a "mega-dose" of T cell-depleted peripheral blood hematopoietic progenitor cells and no posttransplant pharmacological immunosuppression. The absence of posttransplant immunosuppression was an opportunity to discover Natural Killer cell alloreactions that eradicated acute myeloid leukemia and improved survival. Furthermore, it also unveiled the benefits of transplantation from mother donors, a likely consequence of mother-to-child interaction during pregnancy. More recent transplantation protocols use unmanipulated (without exvivo T-cell depletion) haploidentical grafts combined with enhanced posttransplant immunosuppression to help prevent GVHD. Unmanipulated grafts substantially extended the use of haploidentical transplantation with results than even rival those of matched hematopoietic transplantation. In T cell-depleted haploidentical transplantation, recent advances were made by the adoptive transfer of regulatory and conventional T cells.
globulin administration, and it was the only form of GVHD prophylaxis. Less than 10% of patients developed acute and chronic GVHD. With over 15 years follow-up, relapse incidence was 18% in patients with acute myeloid leukemia (AML) and 30% in patients with acute lymphoblastic leukemia (ALL) who were transplanted in any complete remission (CR). 3, 6, [11] [12] [13] In a retrospective European Bone Marrow Transplantation registry-based survey of T cell-depleted haploidentical transplantation in adults with acute leukemia, 2-year relapse incidence was 21% in patients with AML and 27% in patients with ALL in any CR at transplant. 17 T-cell depletion was associated with slow post-transplant immune reconstitution. Indeed, these studies reported ~40% NRM, mainly caused by infections.
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Effectiveness of donor-versus-recipient NK-cell alloreactivity
In T cell-depleted haploidentical transplantation, the absence of any posttransplant immunosuppression favored the emergence of Natural Killer (NK)-cell alloreactions that reduced relapse rates and improved survival. recognizes HLA-C group 2 alleles, KIR2DL2 and KIR2DL3 recognize HLA-C group 1 alleles, and KIR3DL1 is the receptor for HLA-Bw4 alleles. 25-27 NK cells become fully functional ("licensed/educated") upon interaction with self-HLA molecules. 23 Educated NK cells react to the lack of self-HLA expression on allogeneic targets (so-called "missing self recognition"). [28] [29] [30] [31] After hematopoietic transplantation, reconstituting NK cells are educated by HLA KIR ligands on donor hematopoietic cells. 32 In the presence of KIR-ligand mismatches in the graft-versus-host direction (i.e., the donor possesses an HLA-class I KIR ligand that is absent in the recipient), NK cells that express a KIR for an HLA-class I These findings were confirmed in T cell-depleted haploidentical transplantation in children with acute leukemia. 34, 35 The results in T cell-depleted haploidentical transplantation prompted clinical trials that proved safety of NK-cell infusions and documented promising clinical responses in leukemia patients.
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The additional benefit of NK alloreactive donors with concomitant activating KIRs 
Haploidentical transplant protocols using unmanipulated grafts
In recent years, the haploidentical transplantation field saw the development of 
Posttransplant high-dose cyclophosphamide
In murine models, it was shown that posttransplant cyclophosphamide, when given within a narrow, 2-to 3-day, window after T-cell receptor (TCR) stimulation (at the time of peak
For personal use only. on January 22, 2018. by guest www.bloodjournal.org From DNA synthesis), targets recipient and donor activated alloreactive T cells (thus reducing the risk of rejection and GVHD).
10 After a nonmyeloablative conditioning regimen comprised of cyclophosphamide, fludarabine and low dose (2Gy) total body irradiation (TBI) and bone marrow transplantation, the Johns Hopkins and the Fred Hutchinson Cancer Research groups gave high-dose cyclophosphamide (on days +3 and +4) for GVHD prophylaxis (followed by mycophenolate mofetil and tacrolimus). 56 In a recent retrospective study of 372 adult patients with a variety of hematological malignancies, 1-year NRM incidence was 11% and incidences of acute GVHD and 2-year chronic GVHD were 32% and 13%, respectively. Three-year relapse incidence was 46% and progressionfree survival was 40%. 57 The Genoa group used a myeloablative conditioning regimen that comprised thiotepa, busulfan and fludarabine or TBI and fludarabine. 58, 59 In 148 adult patients with a variety of hematological malignancies, they reported 4-year NRM was 14%
and incidences of acute and chronic GVHD were 18% and 20%, respectively. Incidence of relapse-related death was 27%. It was 11% in patients in CR1 at transplant, 26% in patients in CR2 at transplant and 40% in patients transplanted with active disease. With a median follow-up of 430 days, overall survival was 77% in patients in CR1 at transplant, 49% in patients in CR2 at transplant and 38% in patients transplanted with active disease. 59 Other groups used G-CSF-mobilized peripheral blood hematopoietic cell grafts with similar results. 10,60-65 A recent study reported results from a cohort of AML patients (74% in CR1 or CR2 and 26% in relapse at transplant), who received bone marrow or peripheral blood hematopoietic grafts. 66 Incidence of 3-year NRM was 14% after myeloablative conditioning regimens and 9% after reduced intensity conditioning regimens. Incidence of acute GVHD was 16% after myeloablative conditioning regimens and 19% after reduced intensity conditioning regimens. Incidence of 3-year chronic GVHD was 30% after myeloablative conditioning regimens and 34% after reduced intensity conditioning regimens. Three-year relapse incidence was 44% after myeloablative
For personal use only. on January 22, 2018. by guest www.bloodjournal.org From conditioning regimens and 58% after reduced intensity conditioning regimens. Three-year overall survival was ~45% after both myeloablative and reduced intensity conditioning regimens. Three-year chronic GVHD-free/leukemia-free survival was 24% after myeloablative conditioning regimens and 18% after reduced intensity conditioning regimens. 66 In another study, 5-year overall survival was 43% in AML and 32% in ALL patients. 67 Therefore, the main advantages of haploidentical unmanipulated hematopoietic grafts with posttransplant high-dose cyclophosphamide appear to be the relatively low incidences of NRM and severe GVHD.
In-vivo T-cell depletion of G-CSF-mobilized peripheral blood hematopoietic grafts
In-vivo T-cell depletion of G-CSF-mobilized peripheral blood hematopoietic grafts with anti-T cell antibodies is an alternative strategy to prevent GVHD. 68, 69 One study used fludarabine, cyclophosmamide and the humanized anti-CD52 monoclonal antibody alemtuzumab as preparative regimen. 68 Alemtuzumab also exerted in-vivo T-cell depletion of the graft (additional GVHD prophylaxis consisted of mycophenolate mofetil with or without cyclosporine). In 49 patients with hematologic malignancies or marrow failure, NRM rate was 31% and rates of acute and chronic GVHD were 16% and 14%, respectively. One-year overall survival was 31%. 68 Another study in 83 adult patients with acute leukemia or myelodysplastic syndrome (MDS) used busulfan, fludarabine and antithymocyte globulin for in-vivo T-cell depletion (and cyclosporine and methotrexate as additional GVHD prophylaxis). 69 Incidence of NRM was 18% and incidences of acute and chronic GVHD were 20% and 34%, respectively. Incidence of relapse was 27% in acute leukemia patients in CR1 at transplant, 32% in patients in CR≥2 at transplant, 79% in patients transplanted with refractory acute leukemia, and 20% in patients with MDS. After a median follow up of two years, disease-free survival was 60% in acute leukemia patients in CR1 at transplant, 53% in patients in CR≥2 at transplant, 9% in patients transplanted with refractory acute leukemia, and 53% in patients with MDS.
G-CSF-primed hematopoietic grafts combined with in-vivo T-cell depletion
Several studies showed that G-CSF attenuated the risk of GVHD because it decreased production of inflammatory cytokines, increased production of interleukin-10, and induced T-helper-2 and regulatory T-cell immune deviation. 9,78 The Beijing group designed a transplant protocol consisting of G-CSF administration ("priming") before marrow and blood harvesting. GVHD prophylaxis consisted of in-vivo T-cell depletion of the graft with ATG and posttransplant cyclosporine, mycophenolate mofetil and methotrexate. [70] [71] [72] In a study of 1,210 patients with hematologic malignancies, 3-year incidence of NRM was 17% and incidences of acute and chronic GVHD were 40% and 50%, respectively. Three-year relapse incidence was 17% and progression-free survival was 67%. 70 In a cohort of pediatric and adult patients with acute leukemia, NRM was ~25%, and incidences of acute GVHD and 3-year chronic GVHD were 45.8% and 53.9%, respectively. 71 The incidence of relapse was 11.9% in "standard-risk" AML and 24.3% in "standard-risk" ALL ("standard-risk" denotes patients in CR1 or CR2 at transplant, without Philadelphia chromosome), 71 and 20.2% in "high-risk" AML and 48.5% in "high-risk" ALL ("high-risk" denotes patients in CR>2 or nonremission at transplant, or acute leukemia with Philadelphia chromosome in any disease status at transplant). 71 Three-year leukemia-free survival was 70.7% in "standard-risk" AML, 59.7% in "standard-risk" ALL, 55.9% in "highrisk" AML and 24.8% in "high-risk" ALL. 71 In another series of 620 acute leukemia patients, the authors found 3-year leukemia-free survival was 64% in AML and 57% in ALL. 72 Such results appear to be better than those of other studies. Younger age and fewer high-risk leukemia patients might have played a role. 71, 72, 79 The Rome Transplant Network used bone marrow alone and intensified GVHD prophylaxis with the addition anti-CD25
antibody administration. 73, 74 In a cohort of patients with a variety of hematological malignancies, five-year NRM incidence was 34%, acute GVHD incidence was 31% and 2-year chronic GVHD incidence was 25%. 
Enhancing the potency of T cell-depleted haploidentical transplants
Recently, further advances were made to enhance the effectiveness of T cell- used in children with acute leukemia. Three-year relapse incidence was 21.9% and probability of leukemia-free survival was 73.1%. 90 Another promising strategy is adoptive immunotherapy with thymic-derived/natural CD4+CD25+FoxP3+ regulatory T cells (Tregs) 91, 92 in combination with conventional T cells (Tcons). 3, 6, 7, [93] [94] [95] In major histocompatibility complex mismatched bone marrow transplantation murine models, coinfusion of Tregs and Tcons prevented lethal GVHD without impairing Tcon alloreactivity leukemia killing. [94] [95] [96] [97] The mechanisms whereby Tregs protect from GVHD while preserving the Tcon-mediated GVL effect are suggested by experiments in immunodeficient NODscidIL2rgtm mice infused with human leukemia and HLA-mismatched Tregs/Tcons. 95 Human peripheral blood Tregs preferentially migrated to GVHD target organs (i.e., liver and gut) where they prevented GVHD. As they did not to migrate to the bone marrow, coinfused human Tcons were free to exert unopposed alloantigen recognition and leukemia killing. In fact, the infused human peripheral blood Tregs displayed a memory CD45RO+ phenotype and express low levels of the bone marrow homing receptor CXCR4. 95 NRM fell from 52% to 24%. 93, 94 In the entire series of 58 patients, the 5-year relapse incidence was 12%. None of the 14 AML patients transplanted from an NK alloreactive donor relapsed (Figure 1 ). Consequently, in the entire series, 5-year probability of chronic GVHD-free/leukemia-free survival was 50% (Alessandra Carotti, Franca Falzetti, L.R. and A.V., unpublished data, June 30, 2016). [93] [94] [95] 
Conclusions
The 1990s saw what had been major drawbacks of haploidentical transplantation, i.e., very strong host-versus-graft and graft-versus-host alloresponses which led respectively to rejection and GVHD, being overcome through transplantation of a megadose of T cell-depleted peripheral blood hematopoietic progenitor cells. [3] [4] [5] [6] [7] [11] [12] [13] Immune recovery in the absence of any posttransplant immunosuppression created an opportunity for discovering innovative forms of immunotherapy. In conclusion, haploidentical transplantation appears to provide results that even rival those of matched transplantation. 66, [79] [80] [81] [82] [83] [84] [85] [86] Therefore, lack of an HLA-matched donor does not preclude favorable transplantation outcomes.
For BM indicates bone marrow; PB, peripheral blood; NR, not reported; CML, chronic myeloid leukemia. *Graft source was bone marrow in 84% of patients and G-CSF-mobilized peripheral blood hematopoietic cells in 16% of patients. †Outcomes after myeloablative or reduced intensity conditioning regimens, respectively. ‡"Standard-risk": CR1 or CR2 at transplant, without Philadelphia chromosome. §"High-risk": CR≥3 or nonremission at transplant, or acute leukemia with Philadelphia chromosome in any disease status at transplant. ¶Graft source was bone marrow in 44% of patients, G-CSF-mobilized peripheral blood hematopoietic cells in 53% of patients and a combination of the two in 3% of patients. GVHD prophylaxis was based on in-vivo T-cell depletion with anti-T cell antibodies (75%) or posttransplant high-dose cyclophosphamide (13%) or other (12%).
#Graft source was bone marrow in 44% of patients and G-CSF-mobilized peripheral blood hematopoietic cells in 56% of patients. GVHD prophylaxis was based on posttransplant high-dose cyclophosphamide (52%) or in-vivo T-cell depletion with ATG (48%). 18-22, 93, 94 For personal use only. on January 22, 2018. by guest www.bloodjournal.org From
